Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of trastuzumab plus capecitabine combination therapy (HX therapy) and lapatinib plus capecitabine combination therapy (LX therapy) in HER2 positive metastatic or unresectable locally advanced breast cancer with history of trastuzumab and taxane anticancer drugs Randomized comparison II Exploratory study of effect predictors in phase test

Next Previous
Trial Profile

Comparison of trastuzumab plus capecitabine combination therapy (HX therapy) and lapatinib plus capecitabine combination therapy (LX therapy) in HER2 positive metastatic or unresectable locally advanced breast cancer with history of trastuzumab and taxane anticancer drugs Randomized comparison II Exploratory study of effect predictors in phase test

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ELTOP study

Most Recent Events

  • 10 Dec 2016 Status changed from active, no longer recruiting to completed, according to results presente at the 39th Annual San Antonio Breast Cancer Symposium..
  • 08 Jan 2015 New trial record
  • 13 Feb 2014 Planned number of patients changed from 170 to 110 as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top